Review Article

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract: The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Biologicals and biosimilars: a review of the science and its implications

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 13-6

Abstract: Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory… Read More »

A review of generic medicine pricing in Europe

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 08-12

Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is… Read More »

An overview of the current status of follow-on biologicals in Iran

Published in: Volume 10 / Year 2021 / Issue 2
Author(s): ,

Background The advent of follow-on biologicals in Iran and biosimilars worldwide have provided various treatment options for several severe and chronic diseases. The goal of the present study was to… Read More »

The EU biosimilar framework – experience to date. The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes

Author(s): , , , ,

Author byline as per print journal: Marta Zuccarelli1, PharmD; Benjamin Micallef1, PharmD; Mark Cilia1, PharmD; Anthony Serracino-Inglott1, 2, PharmD; Professor John-Joseph Borg1, 3, PhD Introduction/Study Objectives: The development of biosimilars… Read More »

Page 5 of 5 « Previous1 2 3 4 5
Go Back Print